StreetInsider.com News Articles

Veradermics (MANE) PT Raised to $204 at B.Riley

Thu, 22 Oct 2026 08:12:53 -0400

B.Riley analyst Mayank Mamtani raised the price target on Veradermics (NYSE: MANE) to $204.00 (from $170.00) while maintaining a Buy rating.

Veradermics stock surges as hair loss drug meets Phase 3 goals

Mon, 19 Oct 2026 09:24:04 -0400

Investing.com -- Veradermics Inc (NYSE:MANE) shares rose 6.7% in premarket trading Monday after the company announced its oral hair loss drug VDPHL01 met all primary and secondary endpoints in a Phase 3 clinical trial.

The registration-directed Phase 3 trial, Study '304', enrolled 536 male participants with mild-to-moderate pattern hair loss who received either VDPHL01 8.5mg once daily, VDPHL01 8.5mg twice daily, or placebo. VDPHL01 demonstrated increases in target area hair count of 28.6 hairs/cm² for once-daily dosing and 36.4 hairs/cm² for twice-daily dosing, compared to 6.6 hairs/cm² for placebo, with high statistical significance.

Approximately 78.8% of once-daily participants and

Veradermics stock surges as hair loss drug meets Phase 3 goals

Mon, 19 Oct 2026 09:24:04 -0400

Approximately 78.8% of once-daily participants and

Form 8-K Veradermics, Inc For: Oct 19

Mon, 19 Oct 2026 09:06:00 -0400

si-local-file:///var/storage/secattach/20261019/27201689.html

Veradermics' oral hair loss drug meets all Phase 3 endpoints

Mon, 19 Oct 2026 07:00:25 -0400

Veradermics, Incorporated (NYSE: MANE) announced positive topline results from Part A of its Phase 3 clinical trial, Study '304', evaluating VDPHL01, an investigational extended-release oral minoxidil formulation, in 536 males with mild-to-moderate pattern hair loss.

The trial met all primary and secondary endpoints with high statistical significance across both dosing arms. Participants receiving VDPHL01 8.5mg once daily showed a mean increase in non-vellus target area hair count of 28.6 hairs/cm² (p<0.0001), while those receiving 8.5mg twice daily showed an increase of 36.4 hairs/cm² (p<0.0001), compared with 6.6 hairs/cm² for placebo at Month 6.

On patient-reported outcomes, 55.7% of once-daily participants and 68.7%

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss

Mon, 19 Oct 2026 07:00:00 -0400

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01

VDPHL01 demonstrated increases in target area hair count (TAHC) of 28.6 hairs/cm² (once-daily dosing; p<0.0001) and 36.4 hairs/cm² (twice-daily dosing; p<0.0001) versus 6.6 hairs/cm² for placebo at Month 6, a similar mean increase in TAHC that was observed in Study ‘302’

Approximately 78.8% (QD) and 85.0% (BID) of participants reported visible improvement in patient-reported outcomes (PRO) versus 35.3% of placebo participants; 55.7% (QD; p<0.0001) and 68.7% (BID; p<0.0001)

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss

Mon, 19 Oct 2026 07:00:00 -0400

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01
VDPHL01 demonstrated increases in target area hair count (TAHC) of 28.6 hairs/cm² (once-daily dosing; p<0.0001) and 36.4 hairs/cm² (twice-daily dosing; p<0.0001) versus 6.6 hairs/cm² for placebo at Month 6, a similar mean increase in TAHC that was observed in Study ‘302’
Approximately 78.8% (QD) and 85.0% (BID) of participants reported visible improvement in patient-reported outcomes (PRO) versus 35.3% of placebo participants; 55.7% (QD; p<0.0001) and 68.7% (BID; p<0.0001)

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.
While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”
Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.
Given this